3 Dividend Stocks Worth Buying Now?
Thanks to surging stock prices over the past two years, dividend yields on major stock indices have fallen to fairly low levels. The S&P 500, for instance, currently carries an average yield of just 1.3%.
The mature companies in the Dow Jones Industrial Average fare a bit better, and some of them offer yields that exceed the S&P 500 several times over. » Read more about: 3 Dividend Stocks Worth Buying Now? »
Read More
Technical Signals Scream SELL
Correlation and causation can easily be mixed up when trading. Just because markets fall every time something happens doesn’t mean that something is the cause. Nevertheless, when correlations appear, they should be respected, and we just stumbled upon one that, if true, screams it’s time to SELL.
Scary Technical Trend
Over the past year or so,
» Read more about: Technical Signals Scream SELL »
Read More
2 Trading Tips To 2x Your Returns
In 2020, a shocking report revealed that 90% of actively managed portfolios failed to beat the market over a 15 year time horizon.
According to the S&P SPIVA report, a full 88.4% of managed equity funds underperformed the market.
Many of the fund managers are Ivy League-trained with impeccable pedigrees and intellect,
» Read more about: 2 Trading Tips To 2x Your Returns »
Read More
The Ultimate Valentine’s Day Stock To Hold For 10 Years
Some companies have moats that cannot be ignored, and Match Group fits that bill. Match is the company that houses online dating apps, such as Tinder, Hinge and its original flagship site, Match.com. But what makes the stock attractive to own, besides the fact that it’s Valentine’s Day and love is in the air?
Read More
Massive Upside In Big Money Pharma Favorite?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes in the use of immune therapies for cancer treatment. Specifically, Iovance is exploring new applications of tumor infiltrating lymphocyte (TIL) therapy, utilizing cells that the human body naturally produces to attack cancerous tumors.
There was lots of hype about this next-generation cancer treatment company but its share price has been decidedly lackluster this year,
» Read more about: Massive Upside In Big Money Pharma Favorite? »
Read MoreThe Ivy
Will This ETF 2x Before Year End?
In recent months, some of the most sophisticated investors on Wall Street have made a bold move by pouring hundreds of millions into BlackRock’s iShares Bitcoin Trust (IBIT).
This isn’t just a passing trade but a conviction bet that Bitcoin’s best days may still be ahead and while still trading under $100,000 per coin,
» Read more about: Will This ETF 2x Before Year End? »
Read MoreThe Spotlight
Is This Space Firm Set To Blast Off
At an annual conference some years ago, a Berkshire Hathaway shareholder asked Warren Buffett how it was possible for smaller investors to rival his own performance and track record during the 1960s, which was his best period. He corrected the questioner and commented that, in fact, his best years were prior to that in the 1950s when he averaged gains closer to 50% annually.
» Read more about: Is This Space Firm Set To Blast Off »
Read MoreThe Daily
Sebi reduces the expense ratio of mutual fund AMCs. What does it mean for the Indian stock market? Explained
India’s capital market regulator, the Securities and Exchange Board of India (Sebi), has reduced the expense ratio—the annual fee that mutual fund asset management companies (AMCs) charge investors to manage their money. The move is aimed at simplifying how expenses are charged by fund houses, while improving clarity and strengthening investor interests.